iacopo olivotto (@iacopoolivotto) 's Twitter Profile
iacopo olivotto

@iacopoolivotto

inadequate but enthusiastic: physician, clinical investigator, cardiomyopathy expert.

ID: 1302711066581962753

calendar_today06-09-2020 20:51:47

956 Tweet

1,1K Followers

371 Following

Nico Gagelmann (@nicogagelmann) 's Twitter Profile Photo

Elsevier is one of the largest, most hated and most influential academic publishing companies in the world. How it started & how it's going A thread🧵

Elsevier is one of the largest, most hated and most influential academic publishing companies in the world. 

How it started & how it's going

A thread🧵
Enrico Ammirati (@ammiratienrico) 's Twitter Profile Photo

Hypertrophic cardiomyopathy secondary to hydroxychloroquine toxicity in a patient with rheumatoid arthritis - The Lancet thelancet.com/journals/lance…

Novi Yanti Sari (@slumberbell) 's Twitter Profile Photo

It’s almost midnight here⏰, but couldn’t miss all the great insights from the #HFA_ESC journal club 2nd episode; diving deep into the #SEQUOIA_HCM trial!🤩 Huge thank you to all brilliant speakers Sotiria Liori, Juan Pablo Kaski, iacopo olivotto, & wonderful host Antonio Cannata' for a

It’s almost midnight here⏰, but couldn’t miss all the great insights from the #HFA_ESC journal club 2nd episode; diving deep into the #SEQUOIA_HCM trial!🤩

Huge thank you to all brilliant speakers <a href="/SotiriaLiori/">Sotiria Liori</a>, <a href="/jpkaski/">Juan Pablo Kaski</a>, <a href="/IacopoOlivotto/">iacopo olivotto</a>, &amp; wonderful host <a href="/_antocannata/">Antonio Cannata'</a> for a
Niccolo' Maurizi (@mauriziniccolo) 's Twitter Profile Photo

🎯SRT in HCM: long-term evolution & predictors of outcome ? 🥇1832 pts, 10 ys after the SRT: 83% alive.⬆️ age at intervention ⬇️ survival. 🥈13% de novo HF (⬆️age & females) Low SCD over f-up (0.7%) 🥉Peri-procedural outcome in ⬆️ clinical vol HCM centers meets AHA/ACC metrics.

🎯SRT in HCM: long-term evolution &amp; predictors of outcome ?
🥇1832 pts, 10 ys after the SRT: 83% alive.⬆️ age at intervention ⬇️ survival. 
🥈13% de novo HF (⬆️age &amp; females) Low SCD over f-up (0.7%)
🥉Peri-procedural outcome in ⬆️ clinical vol HCM centers meets AHA/ACC metrics.
Circulation (@circaha) 's Twitter Profile Photo

Long term surveillance of patients following successful septal reduction therapies (SRT) in patients with obstructive hypertrophic cardiomyopathy: Insights from the Share Registry ahajournals.org/doi/full/10.11…

Long term surveillance of patients following successful septal reduction therapies (SRT) in patients with obstructive hypertrophic cardiomyopathy: Insights from the Share Registry ahajournals.org/doi/full/10.11…
Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

Now published in JACC Journals - results from the withdrawal of SoC meds in FOREST-HCM (BB/CCB/disopyramide) while on #aficamten sciencedirect.com/science/articl… We presented this previously at ESC2024 x.com/MasriAhmadMD/s… #CardioTwitter

Now published in <a href="/JACCJournals/">JACC Journals</a> - results from the withdrawal of SoC meds in FOREST-HCM (BB/CCB/disopyramide) while on #aficamten 

sciencedirect.com/science/articl… 

We presented this previously at ESC2024 
x.com/MasriAhmadMD/s…

#CardioTwitter
HCM Patient Foundation (@hcmpatient) 's Twitter Profile Photo

Episode II of our webcast #HCMPills is live! In it Dr.Niccolo' Maurizi interviews Prof. iacopo olivotto on the diagnosis, follow-up and life with #HCM. Big thanks to webcast sponsors Bristol Myers Squibb and Cytokinetics! Enjoy and thanks for sharing! ⬇️⬇️⬇️ youtube.com/watch?v=g5m3tK…

Luis Lopes (@luisrlopes77) 's Twitter Profile Photo

Arrhythmic risk stratification in ring-like scar (gene negative and positive) academic.oup.com/eurjpc/article… led by Elena Biagini Bologna’s group with interesting results showing primacy of the ECG. Includes London cohort and other collaborators iacopo olivotto Ana Rita Moura

Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

While these SRT eligibility cut offs are arbitrary - patients do ask the question: what are the chances that this medication can work and allow me to avoid surgery/procedure? These data can help mange such a conversation once aficamten becomes commercially available

While these SRT eligibility cut offs are arbitrary - patients do ask the question: what are the chances that this medication can work and allow me to avoid surgery/procedure? 
These data can help mange such a conversation once aficamten becomes  commercially available
The International HCM Summit (@hcmsummit) 's Twitter Profile Photo

Thank you to everyone who joined us in Boston! If you missed it, HCM8 On-Demand is now available & you can watch our FULL highlight reel at hcmsummit.org. Stay tuned for details on HCM9, returning to Boston in October 2026. #hypertrophiccardiomyopathy #hcmsummit8 #hcm8

The HCM Academy (@thehcmacademy) 's Twitter Profile Photo

Thank you very much to iacopo olivotto, Martin Maron, MD and to everyone who attended our webinar last week! Details of where to watch the on-demand version will be coming soon! Watch this space!👀

Rosa Lillo (@rosalillo14) 's Twitter Profile Photo

Amazing HCM Masterclass in Florence! ⭐Astonishing presentations by 🔝 faculty ⭐Echo live sessions with patients Thank you Professor iacopo olivotto for this beautiful event, looking forward the next edition! Maurizio Pieroni Giuseppe Limongelli Cappelli Francesco francesca graziani_FG

Amazing HCM Masterclass in Florence!
⭐Astonishing presentations by  🔝 faculty
⭐Echo live sessions with patients

Thank you Professor <a href="/IacopoOlivotto/">iacopo olivotto</a> for this beautiful event, looking forward the next edition!

<a href="/mauripieroni72/">Maurizio Pieroni</a> <a href="/glimongelli/">Giuseppe Limongelli</a>
<a href="/Cappellifrance2/">Cappelli Francesco</a> <a href="/FGraziani_Grace/">francesca graziani_FG</a>
Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

Great to see the ongoing and increasing activity in the cardiomyopathy space. Today it was announced that aficamten's application to the FDA for the treatment of symptomatic oHCM was accepted, with a target decision date (PDUFA) of 9/26/2025. #CardioTwitter

Great to see the ongoing and increasing activity in the cardiomyopathy space. Today it was announced that aficamten's application to the FDA for the treatment of symptomatic oHCM was accepted, with a target decision date (PDUFA) of 9/26/2025. 

#CardioTwitter